Search results for "PTO"

showing 10 items of 28599 documents

Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells

2000

Human herpes virus-8 (HHV8) encodes a cytokine named viral interleukin-6 (vIL-6) that shares 25% amino-acid identity with its human homologue. Human IL-6 is known to be a growth and differentiation factor of lymphatic cells and plays a potential role in the pathophysiology of various lymphoproliferative diseases. vIL-6 is expressed in HHV8-associated-diseases including Kaposi's sarcoma, Body-cavity-based-lymphoma and Castleman's disease, suggesting a pathogenetic involvement in the malignant growth of B-cell associated diseases and other malignant tumours. We expressed vIL-6 in Escherichia coli as a fusion protein with recombinant periplasmic maltose binding protein. After cleavage from the…

medicine.medical_treatmentBiologyGlycoprotein 130BiochemistryFusion proteinMolecular biologylaw.inventionMaltose-binding proteinCytokinelawInterleukin-6 receptorbiology.proteinRecombinant DNAmedicineInterleukin 6ReceptorEuropean Journal of Biochemistry
researchProduct

Synthesis of biotin-labelled dexamethasone derivatives. Novel hormone-affinity probes.

1983

A new, general methodology for 'sandwich' affinity chromatography of steroid hormone receptors is proposed, the part purification of the human spleen tumor glucocorticoid receptor is quoted as an illustration. 9-Fluoro-16 alpha-methyl-11 beta, 17-dihydroxy-1,4-androstadiene-3-one-17 beta-carboxylic acid was coupled to biotin using pentamethylenediamine (BioDex 1) as a spacer. The bifunctional derivative binds to glucocorticoid receptors and avidin-Sepharose and efficiently protects the glucocorticoid receptor against inactivation when previously added during homogenisation. We have standardized the capacity and optimum conditions for elution of receptor-BioDex-1 complexes which are bound to…

medicine.medical_treatmentBiotinBiochemistryBinding CompetitiveChromatography AffinityDexamethasoneSteroidchemistry.chemical_compoundGlucocorticoid receptorCytosolReceptors GlucocorticoidAffinity chromatographyBiotinCadaverinemedicineHumansBinding siteReceptorPolyacrylamide gel electrophoresisChromatographyBinding SitesChemistrySplenic NeoplasmsAffinity LabelsSteroid hormoneBiochemistryElectrophoresis Polyacrylamide GelEuropean journal of biochemistry
researchProduct

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells

2013

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is well tolerated, concern for its safety has been expressed. Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells. The present study examined the interaction between celecoxib and sorafenib in two human liver tumor cell lines HepG2 and Huh7. Our data showed that each inhibitor alone reduced cell growth and the combination of celecoxib with sorafenib synergistically inhibited cell growth an…

medicine.medical_treatmentCancer TreatmentGene ExpressionApoptosisPharmacologyBiochemistryTargeted therapy0302 clinical medicineMolecular Cell Biology0303 health sciencesSulfonamidesMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionQLiver NeoplasmsRDrug SynergismGenomicsSorafenib3. Good healthGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisMedicineLiver cancermedicine.drugResearch ArticleBiotechnologySignal TransductionSorafenibNiacinamideProgrammed cell deathCarcinoma HepatocellularScienceBlotting WesternBiologyMolecular Genetics03 medical and health sciencesCell Line TumorGastrointestinal TumorsmedicineIn Situ Nick-End LabelingHumansneoplasmsBiology030304 developmental biologyCell ProliferationDNA PrimersHuman liver cancer Apoptosis Sorafenib Celecoxib anti-proliferative effectsCell growthGene Expression ProfilingPhenylurea CompoundsComputational BiologyCancers and NeoplasmsHepatocellular CarcinomaChemotherapy and Drug Treatmentmedicine.diseaseMicroarray Analysisdigestive system diseasesGene expression profilingApoptosisCell cultureCelecoxibPyrazolesGenome Expression AnalysisPLoS ONE
researchProduct

Recombinant Human Single Chain Fv Antibodies Recognizing Human Interleukin-6

1998

A human antibody library was displayed on the surface of filamentous bacteriophage and screened for binding to human interleukin-6 (IL-6). Two antibody-bearing phages were selected that bound IL-6. The complementary-determining region 3 loops of the variable heavy chains of these two antibodies differed in length and sequence and recognized two distinct epitopes. One of the single chain Fv fragments isolated (H1) was found to bind human (but not murine) IL-6 with an affinity comparable to that of the human IL-6 receptor. H1 also recognized newly synthesized human IL-6 intracellularly, as shown by indirect immunofluorescence. H1 did not neutralize human IL-6, and the H1 epitope was mapped to…

medicine.medical_treatmentCell BiologySingle-Chain FvBiologyGlycoprotein 130biology.organism_classificationBiochemistryMolecular biologyEpitopelaw.inventionCytokineFilamentous bacteriophagelawmedicinebiology.proteinRecombinant DNAAntibodyReceptorMolecular BiologyJournal of Biological Chemistry
researchProduct

Lovastatin stimulates p75 TNF receptor (TNFR2) expression in primary human endothelial cells

2005

HMG-CoA reductase inhibitors (statins) exert pleiotropic physiological effects. Among others they attenuate cellular responses to genotoxic and inflammatory stress. We investigated the effect of lovastatin on the expression level of TNF receptors (TNFR) in primary human endothelial cells (HUVEC). ELISA, FACS and immunocytochemical analyses show that lovastatin selectively increases the cell surface expression of TNFR2 without affecting the expression level of TNFR1. This effect of lovastatin is independent from inhibition of cell-cycle progression since cells both in G1- and G2-phase showed elevated levels of TNFR2 after lovastatin treatment. To analyze the physiological relevance of lovast…

medicine.medical_treatmentCellBiologyDownregulation and upregulationE-selectinpolycyclic compoundsGeneticsmedicineHumansReceptors Tumor Necrosis Factor Type IILovastatinReceptorCells CulturedCell adhesion moleculeCell CycleEndothelial Cellsnutritional and metabolic diseasesGeneral MedicineFlow CytometryUp-RegulationCell biologymedicine.anatomical_structureCytokineReceptors Tumor Necrosis Factor Type ICancer researchbiology.proteinlipids (amino acids peptides and proteins)Tumor necrosis factor alphaLovastatinE-Selectinmedicine.drugInternational Journal of Molecular Medicine
researchProduct

Immune-Inflammatory Responses and Oxidative Stress in Alzheimers Disease: Therapeutic Implications

2010

Alzheimer's disease (AD) is a heterogeneous and progressive neurodegenerative disease which in Western society mainly accounts for clinical dementia. AD has been linked to inflammation and oxidative stress. Neuro-pathological hallmarks are senile plaques, resulting from the accumulation of several proteins and an inflammatory reaction around deposits of amyloid, a fibrillar protein, Abeta, product of cleavage of a much larger protein, the beta-amyloid precursor protein (APP) and neurofibrillary tangles. Inflammation clearly occurs in pathologically vulnerable regions of AD and several inflammatory factors influencing AD development, i.e. environmental factors (pro-inflammatory phenotype) an…

medicine.medical_treatmentCellular homeostasisInflammationmedicine.disease_causeImmune systemAlzheimer DiseaseDrug DiscoverymedicineAnimalsHumansSettore MED/05 - Patologia ClinicaSenile plaquesInflammationSettore MED/04 - Patologia GeneralePharmacologychemistry.chemical_classificationReactive oxygen speciesbusiness.industrymedicine.diseaseOxidative StressCytokinechemistryImmunologyInflammation MediatorsAlzheimer's disease curcuminIL-6 inflammation oxidative stressAlzheimer's diseasemedicine.symptombusinessOxidative stressCurrent Pharmaceutical Design
researchProduct

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct

Feasibility of a personal health technology-based psychological intervention for men with stress and mood problems: Randomized controlled pilot trial

2013

BackgroundWork-related stress is a significant problem for both people and organizations. It may lead to mental illnesses such as anxiety and depression, resulting in increased work absences and disabilities. Scalable interventions to prevent and manage harmful stress can be delivered with the help of technology tools to support self-observations and skills training. ObjectiveThe aim of this study was to assess the feasibility of the P4Well intervention in treatment of stress-related psychological problems. P4Well is a novel intervention which combines modern psychotherapy (the cognitive behavioral therapy and the acceptance and commitment therapy) with personal health technologies to deliv…

medicine.medical_treatmentComputer applications to medicine. Medical informaticsPsychological interventionR858-859.7smartphoneAcceptance and commitment therapylaw.inventionstressNursingRandomized controlled trialSDG 3 - Good Health and Well-beinglawIntervention (counseling)medicineta315mHealthmobile healthtechnology-supported mini-interventionta515Original PaperInternetcognitive behaviour therapybusiness.industryRGeneral MedicinemhealthCognitive behavioral therapyacceptance and commitment therapyMoodAnxietypersonal health technologies/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingMedicinemedicine.symptombusinessClinical psychologyJournal of Medical Internet Research, Research Protocols
researchProduct

The Role of the Amygdala in the Extinction of Conditioned Fear

2006

The amygdala has long been known to play a central role in the acquisition and expression of fear. More recently, convergent evidence has implicated the amygdala in the extinction of fear as well. In rodents, some of this evidence comes from the infusion of drugs directly into the amygdala and, in particular, into the basolateral complex of the amygdala, during or after extinction learning. In vivo electrophysiology has identified cellular correlates of extinction learning and memory in the lateral nucleus of that structure. Human imaging experiments also indicate that amygdaloid activity correlates with extinction training. In addition, some studies have directly identified changes in mole…

medicine.medical_treatmentConditioning ClassicalCentral nervous systemReceptors N-Methyl-D-AspartateAmygdalaExtinction PsychologicalCannabinoid Receptor ModulatorsBasal gangliamedicineAnimalsBiological PsychiatryFear processing in the brainFearsocial sciencesExtinction (psychology)AmygdalaEndocannabinoid systemhumanitiesmedicine.anatomical_structurenervous systemCalcium ChannelsCannabinoidPsychologyNeurosciencepsychological phenomena and processesBasolateral amygdalaBiological Psychiatry
researchProduct

Optimized culture conditions for tissue explants of uterine leiomyoma

2012

Background Uterine leiomyomas are the most common benign tumours in women, which arise from smooth muscle cells of the uterine myometrium and usually are multicentric. In spite of their frequency pathogenesis is widely unknown, mainly due to the absence of a suitable model system. We describe the systematic optimization of culturing leiomyoma tissue explants in an economical and effective ex vivo system. Methods Different concentrations of oxygen, different media, sera, hormones, and growth factor supplements were tested. Immunohistochemical stainings with antibodies against hormone receptors as well as specifying proliferation and apoptotic indices and real-time PCR were performed. Results…

medicine.medical_treatmentCulture Media; Epidermal Growth Factor; Estradiol; Female; Humans; Immunohistochemistry; Leiomyoma; Progesterone; RNA Messenger; Real-Time Polymerase Chain Reaction; Uterine NeoplasmsBiologyReal-Time Polymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyAndrologyTissue culturemedicineHumansRNA MessengerUterine NeoplasmProgesteroneUterine leiomyomaEpidermal Growth FactorEstradiolLeiomyomaGrowth factorMyometriummedicine.diseaseImmunohistochemistrySettore MED/40 - Ginecologia E OstetriciaCulture MediaLeiomyomaHormone receptorUterine NeoplasmsFemaleEx vivoHuman
researchProduct